Part, Chapter, Paragraph
1 II, 5. 5. 3 | 161-7.~Knapp M, McDaid D, Mossialos E, Thornicroft G (2007):
2 IV, 11. 1. 3 | tighter regulatory mechanisms (Mossialos and Le Grand, 1999; Cutler,
3 IV, 11. 1. 4 | not, or less, able to pay (Mossialos and Thomson 2003) (see Section
4 IV, 11. 1. 4 | this additional coverage (Mossialos and Thomson 2004; Colombo
5 IV, 11. 1. 4 | subject of debates (Oliver and Mossialos, 2004). Equal access (for
6 IV, 11. 1. 5 | control spending (Walley and Mossialos, 2004). While it is difficult
7 IV, 11. 1. 5 | prescribing suitability (Mossialos et al, 2004). In the UK,
8 IV, 11. 1. 5 | skewing health outcome data (Mossialos et al, 2007).~ ~There are
9 IV, 11. 1. 5 | overly bureaucratic schemes (Mossialos et al 2007). Thus, it would
10 IV, 11. 1. 5 | these could be prevented (Mossialos et al, 2007).~ ~In the US,
11 IV, 11. 1. 6 | may be up to 25% of costs (Mossialos and Thomson 2004). The costs
12 IV, 11. 3. 2 | at 26% lower) (Mrazek and Mossialos, 2004). Reference pricing
13 IV, 11. 3. 2 | only on a short-term basis (Mossialos et al, 2006).~ ~Profit control
14 IV, 11. 3. 2 | does encourage innovation (Mossialos et al, 2006).~ ~Reimbursement
15 IV, 11. 3. 2 | Netherlands and Sweden (Mossialos et al, 2006).~ ~The substitution
16 IV, 11. 3. 2 | quality assurance mechanisms (Mossialos et al, 2005).~ ~Data and
17 IV, 11. 6. 1 | or increasing efficiency (Mossialos and Dixon, 2002).~ ~Rising
18 IV, 11. 6. 1 | important to note (Kanavos and Mossialos, 1999).~ ~Table 11.9. Total
19 IV, 11. 6. 2 | Thomson, Foubister and Mossialos 2008). In addition, local
20 IV, 11. 6. 2 | administrative economies of scale (Mossialos and Dixon, 2002). However,
21 IV, 11. 6. 2 | public health policies (Mossialos et al, 2000).~ ~Countries
22 IV, 11. 6. 2 | Thomson, Foubister and Mossialos, 2008) (see Section 11.8.
23 IV, 11. 6. 2 | Thomson, Foubister and Mossialos 2008). However, the tax
24 IV, 11. 6. 2 | length from government (Mossialos and Dixon, 2002). However,
25 IV, 11. 6. 2(4)| Thomson, Foubister and Mossialos 2008).~
26 IV, 11. 6. 2 | Thomson, Foubister and Mossialos 2008) (see below for more
27 IV, 11. 6. 2 | Thomson, Foubister and Mossialos 2008).~ ~Relying on health
28 IV, 11. 6. 2 | Thomson, Foubister and Mossialos 2008).~ ~In France, “general
29 IV, 11. 6. 2 | in Thomson, Foubister and Mossialos 2008).~ ~The 2006 Health
30 IV, 11. 6. 2 | Netherlands, Spain and the UK) (Mossialos and Dixon, 2002).~ ~PHI
31 IV, 11. 6. 2 | supplementary or complementary (Mossialos and Thomson, 2004). Substitutive
32 IV, 11. 6. 2 | van Doorslaer et al, 2004; Mossialos and Thomson, 2004). Complementary
33 IV, 11. 6. 2 | complementary insurance) (Mossialos and Thomson, 2004) (Thomson
34 IV, 11. 6. 2 | Thomson, Foubister and Mossialos 2008).~ ~Following legislative
35 IV, 11. 6. 2 | in Thomson, Foubister and Mossialos 2008). This widespread increase
36 IV, 11. 6. 2 | in Thomson, Foubister and Mossialos 2008).~ ~All EU Member States
37 IV, 11. 6. 2 | Thomson, Foubister and Mossialos 2008).~ ~Although all European
38 IV, 11. 6. 2 | Thomson, Foubister and Mossialos 2008).~ ~Table 11.13. Examples
39 IV, 11. 6. 3 | redistribution is relatively flat (Mossialos and Dixon, 2002).~ ~Among
40 IV, 11. 6. 4 | Thomson, Foubister and Mossialos 2008). In Austria and Germany (
41 IV, 11. 6. 4 | Thomson, Foubister and Mossialos 2008).~ ~Purchasing refers
42 IV, 11. 6. 4 | Thomson, Foubister and Mossialos 2008). In order to allocate
43 IV, 11. 6. 4 | Thomson, Foubister, and Mossialos 2008). At the same time,
44 IV, 11. 6. 5 | Economics.~ ~Kanavos P, Mossialos E (1999): "International
45 IV, 11. 6. 5 | Community. W.W. Holland and E. Mossialos. Aldershot: Ashgate~ ~Ministry
46 IV, 11. 6. 5 | Economics 11: 199–205.~ ~Mossialos E, Brogan D et al. (2006): "
47 IV, 11. 6. 5 | Security Review 59(3): 3-25.~ ~Mossialos E, Merkur S et al. (2006):
48 IV, 11. 6. 5 | Security Institutions.~ ~Mossialos E, Dixon A Eds. (2002):
49 IV, 11. 6. 5 | Systems and Policies.~ ~Mossialos E, Dixon A et al. (2000): "
50 IV, 11. 6. 5 | NHS." BMJ 320: 197-8.~ ~Mossialos E, Le Grand J Eds. (1999):
51 IV, 11. 6. 5 | Union. Ashgate, Aldershot.~ ~Mossialos E, Mrazek M et al. (2004):
52 IV, 11. 6. 5 | Pharmaceuticals in Europe. E. Mossialos, M. Mrazek and T. Walley.
53 IV, 11. 6. 5 | Open University Press.~ ~Mossialos E, Thomson S (2004): Voluntary
54 IV, 11. 6. 5 | Systems and Policies.~ ~Mossialos E, Walley T et al. (2004):
55 IV, 11. 6. 5 | equity and quality. E. Mossialos, T. Walley and M. Mrazek.
56 IV, 11. 6. 5 | Systems and Policies.~ ~Mossialos E, Walley T et al. (2005): "
57 IV, 11. 6. 5 | 5(1): 81-93.~ ~Mrazek M, Mossialos E (2004): Regulating pharmaceutical
58 IV, 11. 6. 5 | equity and quality. E. Mossialos, M. Mrazek and T. Walley.
59 IV, 11. 6. 5 | Nuffield Trust~ ~Oliver A, Mossialos E (2004): "Equity of access
60 IV, 11. 6. 5 | options for Europe. E. Mossialos, A. Dixon, J. Figueras and
61 IV, 11. 6. 5 | options for Europe. E. Mossialos, A. Dixon, J. Figueras and
62 IV, 11. 6. 5 | of Canada.~ ~Thomson S, Mossialos E et al. (2003): Cost sharing
63 IV, 11. 6. 5 | Social Affairs.~ ~Thomson S, Mossialos E et al. (2004): Health
64 IV, 11. 6. 5 | University Press.~ ~Walley T, Mossialos E (2004): Financial incentives
65 IV, 11. 6. 5 | Pharmaceuticals in Europe. E. Mossialos, M. Mrazek and T. Walley.
